| Geodon Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Geodon 20 mg | powder for injection | intramuscular | 1.0 each | OTC |
| Geodon 80 mg | capsule | oral | 1.0 each | OTC |
| Geodon 20 mg | capsule | oral | 1.0 each | OTC |
| Geodon 40 mg | capsule | oral | 1.0 each | OTC |
| Geodon 60 mg | capsule | oral | 1.0 each | OTC |
Posted by sandydevore2008 about 12 hours ago
I was on 80mg of Geodon for about 1 year. I started having uncontrolled eye and neck movements. I was taken off the drug. H...
Posted by sandydevore2008 about 12 hours ago
I was on 80mg of Geodon for about 1 year. I started having uncontrolled neck and eye movements. The Dr. took me off immedia...
Posted by justadeb 12 days ago
I just begun with Geodon so my dose is low, 20 mg bid for 3 days, 40 mg bid x 3 days, then up to 60 mg bid. I also take Effex...
Portsmouth area Senior News - Portsmouth Herald News
Note: At this time future trips will be arranged through GeoDon Tours and Travel. Phone: 772-6071 or (800) 863-5811 to get information or to request ...
Wed Mar 05 06:13:33 -0500 2008
Ambling toward patent cliff, flinty Pfizer boasts of pipeline - Medical Marketing and Media
all 3 news articles
Thu Mar 06 12:31:15 -0500 2008
Portsmouth area Senior News - Portsmouth Herald News
Note: At this time future trips will be arranged through GeoDon Tours and Travel. Phone: 772-6071 or (800) 863-5811 to get information or to request ...
Wed Mar 05 06:13:33 -0500 2008
ziprasidone hydrochloride monohydrate
ziprasidone mesylate - The mesylate salt form of ziprasidone, a benzothiazolylpiperazine derivative and an atypical antipsychotic agent with an antischizophrenic property. Ziprasidone mesylate functions as an antagonist at the dopamine D2 and serotonin 5-HT2A and 5-HT1D receptors, and as an agonist at the 5-HT1A receptor. Ziprasidone mesylate also inhibits the synaptic reuptake of serotonin and norepinephrine. The mechanism of action by which ziprasidone mesylate exerts its antischizophrenic effect is unknown but is potentially mediated through a combination of dopamine D2 and serotonin 5-HT2 antagonism. This agent also has antagonistic activity against histamine H1 and alpha1-adrenergic receptors.